| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. | Director | Common Stock, par value $0.01 per share | 643,885 | 12 May 2025 | Direct | ||
| Apimeds Pharmaceuticals US, Inc. | Director | Stock Option (right to buy) | 10,000 | 11 Nov 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| APUS | Apimeds Pharmaceuticals US, Inc. | 11 Nov 2025 | 1 | $0 | 4 | Director | 13 Nov 2025, 18:37 |
| APUS | Apimeds Pharmaceuticals US, Inc. | 15 Oct 2025 | 1 | $0 | 4 | Director | 17 Oct 2025, 19:17 |
| APUS | Apimeds Pharmaceuticals US, Inc. | 16 May 2025 | 1 | $0 | 4 | Director | 20 May 2025, 16:38 |
| APUS | Apimeds Pharmaceuticals US, Inc. | 12 May 2025 | 1 | +$56,715 | 4 | Director | 14 May 2025, 17:58 |
| APUS | Apimeds Pharmaceuticals US, Inc. | 04 Mar 2025 | 0 | $0 | 3 | Director | 08 May 2025, 17:31 |